Company / Capital Expenditures
AbCellera Biologics Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$42.8M
FY2025
5-year range
$4.0M / $78.4M
FY2021-FY2025
Trend
-45.4%
vs FY2024
Sector context
#28 of 194
Health Care
What the data says
AbCellera Biologics Inc.'s capital expenditures of $43M is higher than 86% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 7 years, ranging from $4M in FY2021 to $78M in FY2024.
Based on SEC 10-K filings.
$43M in FY2025 with a 5-year CAGR of +34.6%. Top quartile in the Health Care sector.
Declined from $77M to $43M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +64.1%
- 5-Year CAGR
- +34.6%
- 10-Year CAGR
- -
Sector benchmark
-63.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +34.6%, indicating consistent growth.
- In FY2025, capital expenditures decreased 45.4% year-over-year.
- Ranks #28 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.8M | -45.4% |
| FY2024 | $78.4M | +1.9% |
| FY2023 | $76.9M | +695.5% |
| FY2022 | $9.7M | +142.0% |
| FY2021 | $4.0M | -58.7% |
| FY2020 | $9.7M | +142.0% |
| FY2019 | $4.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026